Homepage Top Section1

Licensed from the Oxford University, the AZD1222 vaccine candidate had delivered strong immune responses against the Covid-19 causing SARS-CoV-2 virus in all participants in a phase I/II trial

Both companies have not disclosed the financial terms of the deal. The research will include the application of GeneCentric’s advanced RNA-based molecular profiling platform to illustrate the potential

The acquisition of KaNDy Therapeutics will allow Bayer to expand its drug development pipeline in women’s healthcare. The deal also allows KaNDy Therapeutics to secure potential milestone payments

BLENREP has been approved as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have secured at least four prior therapies including an anti-CD38

The companies said that rapid recovery was seen in patients on ventilators and extracorporeal membrane oxygenation (ECMO) and having severe medical comorbidities following three days of treatment with

The hAd5 vaccine, which contains the spike (S) and also the nucleocapsid (N) SARS-CoV-2 proteins (hAd5 S + N), delivered strong T cell and humoral immune responses against

Evidence has not emerged yet on how long coronavirus antibodies could protect against the disease, noted Bloomberg. Also, data from early trials have not demonstrated that a vaccine

In the DAPA-CKD trial that featured 4,304 adult patients, Farxiga 10mg, when compared to placebo, delivered a statistically significant and clinically meaningful impact on its primary endpoint of

Remsima, which is an infliximab biosimilar, has now been indicated for the treatment of adults having ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis. Its latest approval